News

The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. Biogen announces new nusinersen trial in broad patient population

    Biogen has announced that it will conduct a new global clinical trial,  DEVOTE. The study will evaluate if higher dosing of nusinersen can provide  improved efficacy in the treatment of SMA across a broad population of patients. The study aims to further build on the long-term safety profile and efficacy of nusinersen in a projected […]

    READ MORE

  2. A community update from Biogen

    Following a request from SMA Europe, Biogen has released the following community updates on: Access to Spinraza™ : 28 European countries now have access to Spinraza™ for 5q SMA Types I, II and III, via regular reimbursement but in some cases, including age restrictions. Additionally, in certain countries there are rare disease/ medical committees who […]

    READ MORE

  3. Potential SMA Treatment granted orphan medicinal product designation by the European Medicines Agency (EMA)

    Cytokinetics announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation to reldesemtiv for the potential treatment of SMA. Reldesemtiv is a drug that has been shown, in the laboratory, to increase the force generated by skeletal muscle and which delays the onset and extent of muscle fatigue. This could be beneficial to people living with SMA […]

    READ MORE